Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major public health concern globally. Often studied in the context of hospital outbreaks, little is known about the persistence and evolutionary dynamics of endemic CRAB populations. A three-month prospective observational study was conducted in a 28-bed intensive care unit (ICU) in Hangzhou, China. A total of 3985, 964 and 119 samples were collected from the hospital environment, patients and staff, respectively. CRAB were isolated from 10.75% of collected samples (n = 551) and whole-genome sequenced. The ICU CRAB population was dominated by OXA-23-producing global clone 2 isolates (99.27 % of all isolates) that could be divided into 20 distinct clusters. CRAB was persistently present in the ICU, driven by regular introductions of distinct clusters. The hospital environment was heavily contaminated, with CRAB isolated from bed units on 183/335 (54.63 %) sampling occasions but from patients on only 72/299 (24.08 %) occasions. CRAB was spread to adjacent bed units and rooms and following re-location of patients within the ICU. We also observed that, over the course of this study, three different plasmids had transferred between CRAB strains in the ICU. The epidemiology of CRAB in this setting contrasted with previously described clonal outbreaks in high-income countries, highlighting the importance of environmental CRAB reservoirs in ICU epidemiology. There is an urgent need for targeted infection prevention and control interventions in endemic settings that can address the global threat posed by this against this multidrug-resistant opportunistic pathogen.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was undertaken as part of the DETECTIVE research project funded by the Medical Research Council (MR/S013660/1) and National Natural Science Foundation of China (81861138054, 32011530116, 31970128). W.v.S was also supported by a Wolfson Research Merit Award (WM160092).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was conducted under the framework of the mandatory surveillance program of Sir Run Run Shaw hospital for carriage of CRE. The Ethics review committee of Zhejiang University School of Medicine granted a waiver to use anonymised isolates for this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw sequence data for all isolates is available via National Center for Biotechnology Information under BioProject accession PRJNA738868.
